Publicacións (73) Publicacións de Miguel Ángel Hernández Pérez

2024

  1. Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2

  2. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  3. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

  4. Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence , Vol. 18, pp. 1163-1171

  5. Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 91

  6. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I)

    Revista de neurologia, Vol. 79, Núm. 1, pp. 21-29

  7. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II)

    Revista de neurologia, Vol. 79, Núm. 2, pp. 51-66

2023

  1. Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

    Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1795-1807

  2. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  3. Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study

    European Neuropsychopharmacology, Vol. 67, pp. 53-65

  4. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  5. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Expert-Agreed Practical Recommendations on the Use of Cladribine

    Neurology and Therapy

  4. What about the weekend effect? Impact of the day of admission on in-hospital mortality, length of stay and cost of hospitalization

    Journal of Healthcare Quality Research, Vol. 37, Núm. 6, pp. 366-373

2021

  1. Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure

    Frontiers in Neurology, Vol. 12

  2. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry

    PLoS ONE, Vol. 16, Núm. 10 October

2020

  1. Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 6, Núm. 3

  2. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

    Frontiers in Neurology, Vol. 11